Using qHTS we identified the combination of HSP90 and PI3K inhibitors as one of the most efficacious drug therapies in ACC and validated the efficacy in vitro and in vivo using ACC PDOs and xenografts, respectively. This evidence concerns the gene PIK3CG and adrenal cortex carcinoma.